Lupin Launches Biosimilar Ranibizumab in Europe

Lupin Limited announced that its commercial partner, Sandoz, has launched RanluspecTM, Lupin's biosimilar Ranibizumab, across Europe (excluding Germany). This launch follows the European Commission's approval of RanluspecTM in vial and pre-filled syringe presentations. The drug is used to treat various retinal diseases, including neovascular age-related macular degeneration and diabetic macular edema. This European launch is a significant step in Lupin's strategy to expand access to high-quality biologic treatments for patients with retinal and choroidal vascular diseases, leveraging its scientific expertise and manufacturing capabilities in biologics.